Detail

Basic Information Clinical Results Relationship Graph

Gene symbol	ROR1	Synonyms	NTRKR1, dJ537F10.1	Type of gene	protein-coding
Chromosome	1	Map location	1p31.3	dbXrefs
Gene perturbation-related omics dataset	PerturbAtlas
Description	receptor tyrosine kinase like orphan receptor 1

GTO ID	GTC0298
Trial ID	NCT02706392
Disease	Chronic Lymphocytic Leukemia \| Acute Lymphoblastic Leukemia \| Mantle Cell Lymphoma \| Lung Non-Small Cell Carcinoma \| Triple-Receptor Negative Breast Cancer
Altered gene	ROR1
Therapeutic/Target gene	Target gene
Therapy	CAR-T cell
Treatment	ROR1 CAR-T cells
Generation	2nd
Phase	Phase1
Recruitment status	Terminated
Title	Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies
Year	2016
Country	United States
Company sponsor	Fred Hutchinson Cancer Center
Other ID(s)	9330\|NCI-2015-01753\|9330\|RG9215045\|2R01CA114536

Vector information

Vector	lentivirus
Construct	scFv-4-1BB-CD3ζ
Vector type	MP71 retroviral vector
Transgene/Inserted gene	receptor tyrosine kinase-like orphan receptor 1 (ROR1)

Cohort1: dose level 1_CLL_MCL_ALL

Administration route	intravenous infusion
Dosage	3.3E5 cells/kg
Donor type	Autologous
Pts	2
Age	Adult, Older_Adult
Lymph depletion	Yes
Adverse reactions	1/2(All-cause mortality); 1/2(Blood and lymphatic system disorders)
References	PMID: 33357452

Cohort2: dose level 2_CLL_MCL_ALL

Administration route	intravenous infusion
Dosage	1E6 cells/kg
Donor type	Autologous
Pts	1
Age	Adult, Older_Adult
Adverse reactions	1/1(Blood and lymphatic system disorders; Respiratory, thoracic and mediastinal disorders)
References	PMID: 33357452

Cohort3: dose level 1_NSCLC_TNBC

Administration route	intravenous infusion
Dosage	3.3E5 cells/kg
Donor type	Autologous
Pts	2
Age	Adult, Older_Adult
Adverse reactions	2/2(All-cause mortality); 1/2(General disorders; Respiratory, thoracic and mediastinal disorders; Vascular disorders)
References	PMID: 33357452

Cohort4: dose level 2_NSCLC_TNBC

Administration route	intravenous infusion
Dosage	1E6 cells/kg
Donor type	Autologous
Pts	3
Age	Adult, Older_Adult
Adverse reactions	2/3(All-cause mortality); 2/3(Blood and lymphatic system disorders; General disorders; Injury, poisoning and procedural complications; Musculoskeletal and connective tissue disorders; )
References	PMID: 33357452

Cohort5: dose level 3_NSCLC_TNBC

Administration route	intravenous infusion
Dosage	3.3E6 cells/kg
Donor type	Autologous
Pts	11
Age	Adult, Older_Adult
Adverse reactions	5/11(All-cause mortality); 10/11(General disorders; Immune system disorders; Vascular disorders)
References	PMID: 33357452

Cohort6: dose level 4_NSCLC_TNBC

Administration route	intravenous infusion
Dosage	1E7 cells/kg
Donor type	Autologous
Pts	2
Age	Adult, Older_Adult
Adverse reactions	2/2(All-cause mortality); 2/2(General disorders; Immune system disorders; Nervous system disorders; Respiratory, thoracic and mediastinal disorders)
References	PMID: 33357452

Overview of Knowledge Graph